1. Introduction {#sec1-jcm-07-00246}
===============

Irinotecan hydrochloride (CPT-11), a semisynthetic derivative of camptothecin, is an anticancer drug that inhibits nucleic acid synthesis by topoisomerase I inhibition \[[@B1-jcm-07-00246]\]. CPT-11 possesses a wide antitumor spectrum. However, diarrhea, a characteristic adverse effect of CPT-11, is often severe and a major reason for discontinuing it. The diarrhea in patients receiving CPT-11 is caused by enterocolitis associated with retained SN-38, which is an active metabolite of CPT-11, in the intestine \[[@B2-jcm-07-00246]\]. Most SN-38 is inactivated by formation of SN-38-glucuronide conjugates and excreted in the bile. However, SN-38-glucuronide conjugate is deconjugated with β-glucuronidase from intestinal microflora \[[@B3-jcm-07-00246]\] to SN-38, which cause diarrhea \[[@B2-jcm-07-00246]\].

Kampo medicine (Japanese herbal medicine) Hangeshashin-to (TJ-14), which contains baicalein, is prepared from seven medicinal herbs including *Pinelliae tuber*, *Scutellariae radix*, *Glycyrrhizae radix*, *Zizyphi fructus, Ginseng radix*, *Coptidis rhizome*, and *Zingiberis siccatum rhizoma*. TJ-14 is generally prescribed to treat gastrointestinal diseases such as diarrhea and gastroenteritis in Japan. Baicalein, an inhibitor of β-glucuronidase, inhibits deconjugation of SN-38-glucuronide conjugate and ameliorates diarrhea induced by CPT-11 in rats \[[@B4-jcm-07-00246]\]. TJ-14 was reportedly effective in preventing and controlling diarrhea associated with CPT-11 in 41 patients with non-small cell lung cancer \[[@B5-jcm-07-00246]\]. However, this early study was small and did not include patients with malignancies other than non-small cell lung cancer. Whether TJ-14 improves tolerability of CPT-11 has thus not yet been clearly determined.

In this study, we aimed to examine the influence of TJ-14 on tolerability of CPT-11 by comparing in-hospital mortality and dosage in early courses of chemotherapy with CPT-11 between patients who did and did not receive TJ-14, data being extracted from a national inpatient database in Japan.

2. Materials and Methods {#sec2-jcm-07-00246}
========================

2.1. Data Source {#sec2dot1-jcm-07-00246}
----------------

In this retrospective cohort study, data were extracted from the Diagnosis Procedure Combination database \[[@B6-jcm-07-00246]\], a national inpatient database that includes the following: patient age, sex, body height and weight, primary diagnosis, TNM classification, Charlson comorbidity index, activities of daily living scores, medications during hospitalization, discharge status, and prefecture codes. This study was approved by the Institutional Review Board of The University of Tokyo, which waived the requirement for informed patient consent because of the anonymous nature of the data, (ethic code: 3501).

In this study, the first episode of hospitalization for chemotherapy with CPT-11 treatment during the study period was evaluated, the intention being to evaluate the earliest course, ideally the first course, of chemotherapy with CPT-11.

2.2. Patient Selection {#sec2dot2-jcm-07-00246}
----------------------

Data on patients who had been treated with CPT-11 with a diagnosis of neoplasm defined by the International Statistical Classification of Diseases and Related Health Problems-10th revision (ICD-10) codes between July 2010 and March 2016 were collected. Patients who had received TJ-14 before or on the day of initial CPT-11 administration during hospitalization were defined as in the TJ-14 group and the remaining patients were defined as in the control group.

2.3. Variables {#sec2dot3-jcm-07-00246}
--------------

The following variables were studied: age, sex, body mass index (kg/m^2^), activities of daily living scores, and items in the TNM staging system. The following cancer types, for which CPT-11 has been approved by the Ministry of Heath, Labour and Welfare were identified: colon cancer (ICD-10 codes, C18, C19, C20), lung cancer (C34), gastric cancer (C16), ovarian cancer (C56), pancreatic cancer (C25), non-Hodgkin lymphoma (C82, C83, C85, B212), breast cancer (C50), skin cancer (C44, C519, C609, C632), and other cancers. The following comorbidities were also identified using ICD-10 codes: chronic obstructive pulmonary disease (J41, J42, J43, J44), interstitial pneumonia (B221, J701, J704, J841, J848, J849, J990, J991, M321, M330, M331, M332, M351), congestive heart failure (E059, I46, I50, I099, I110), ischemic heart disease (I20-25), tachycardia (I47-49, R000, T818), pulmonary thromboembolism (I26), chronic liver disease (B89, B181, B182, B659, B661, K702, K703, K72, K74, K761, K762, K763, K766, K767), chronic renal failure (E102, E112, E142, I120, N17-19), autoimmune diseases (M05, M06, M08, M30-35), mycosis (A420, A43, B37, B380-382, B390-392, B400-402, B410, B420, B440, B441, B449, B460, J172), and bacterial pulmonary infection (A481, J100, J110, J12-16, J170, J178, J18, J85, J86). Procedures and treatments during hospitalization, including surgery with general anesthesia, intensive care unit hospitalization, mechanical ventilation, and hemodialysis were also examined, as was use of drugs that can be used to treat diarrhea, including loperamide hydrochloride, berberine chloride hydrate, and lactomin. Use of drugs that can be used to treat or prevent myelosuppression, such as filgrastim, lenograstim, nartograstim, and pefilgrastim was also examined.

2.4. Primary Outcomes {#sec2dot4-jcm-07-00246}
---------------------

The outcomes of this study were (i) in-hospital death, and (ii) frequency and total amount of CPT-11 administered during hospitalization.

2.5. Statistical Analyses {#sec2dot5-jcm-07-00246}
-------------------------

Continuous variables are presented as mean and standard deviation (SD) or median with interquartile range (IQR). Mann-Whitney U tests were performed to compare frequencies and total amount of CPT-11 between patients who did and did not receive TJ-14. In-hospital deaths were compared between patients who did and did not receive TJ-14 using Pearson's χ^2^ test. (i) Stabilized inverse probability of weighting (IPTW) analyses using propensity scores and (ii) instrumental variable (IV) analyses were performed to compare the outcomes between patients who did and did not receive TJ-14 to account for differences in each individual patient's background characteristics.

Stabilized IPTW employs propensity scores and adjusts for measured potential confounding \[[@B7-jcm-07-00246]\] while preserving sample size. To control for imbalance in covariates, patient's specific stabilized weights were generated using propensity scores, which predict probability of initiating TJ-14. Balance of covariates was assessed by using standardized mean difference; \<0.1 indicates acceptable balancing of covariates between the two groups. Stabilized IPTW analyses preserves sample size and appropriately estimates average treatment effects over marginal distribution of measured covariates in a study cohort. To estimate the propensity score, a logistic regression model for receiving TJ-14 as a function of relevant patient characteristics was constructed. These characteristics included age, sex, body mass index, activities of daily life scale (Barthel index), cancer types, T, N and M factors, medicines for treating diarrhea and febrile neutropenia, surgery with general anesthesia, intensive care unit hospitalization, mechanical ventilation, hemodialysis, comorbidities, season of admission, and geographical area of residence.

IV analyses were conducted to confirm the results of stabilized IPTW analyses because hidden biases caused by unmeasured confounders are not removed with the stabilized IPTW method. The IV method is another means of creating a pseudorandomized situation and technically enables controlling for unmeasured confounders. The followings are the key assumptions of the IV: (i) the IV is highly correlated with the treatment assigned; (ii) it is not correlated with any measured or unmeasured patient characteristics; and (iii) it does not affect patient outcomes except through the studied treatment \[[@B8-jcm-07-00246]\]. In general, individual physicians and hospitals have preferences for therapy for managing adverse drug reaction caused by anticancer agents. When use of herbal medicine such as TJ-14 is strongly consistent within a hospital, decisions about supportive therapy for anticancer agents is presumably made independently of individual patient's characteristics. Thus, for such hospitals, using TJ-14 depends more on the hospital at which a patient is treated than on that patient's specific risk factors. Under these circumstances, the hospital's preference for herbal medicine as supportive therapy for anticancer agents was considered to act as an IV, even in the presence of unmeasured confounders. In this study, "the percentage of TJ-14 use in each hospital", which was calculated by dividing the number of patients receiving TJ-14 by the number receiving CPT-11, was used as an IV. The F-test was used to identify weak instrument; F-statistic \<10 being considered to denote a weak IV \[[@B9-jcm-07-00246]\]. To ensure for robustness, this IV was used in a two stages residual inclusion method to compute incidence rate ratios of frequency and total amount of CPT-11 administered and the odds ratio of in-hospital death between the two groups in a generalized liner model. Logistic regression was conducted for in-hospital death and Poisson regression for frequency and total amount of CPT-11 administered in both propensity-score stabilized IPTW and IV analyses.

All statistical analyses were performed using SPSS version 23.0 (IBM SPSS, Armonk, NY, USA) and Stata version 15.1 (StataCorp, College Station, TX, USA). A two tailed significance level of 0.05 was used in all statistical analysis.

3. Results {#sec3-jcm-07-00246}
==========

3.1. Patient Characteristics {#sec3dot1-jcm-07-00246}
----------------------------

We identified 90,437 patients who had received chemotherapy with CPT-11 and 7239 who had received TJ-14 before or on the same day they received CPT-11. The baseline characteristics of all patients (*N* = 90,437) and patients after stabilization by IPTW estimation (*N* = 89,111) are shown in [Table 1](#jcm-07-00246-t001){ref-type="table"}. Among all patients, larger proportions of patients with lung and ovarian cancer received TJ-14, whereas smaller proportions of patients with colon and gastric cancer received TJ-14. We have provided detailed information on cancer types of all patients in [Supplementary Table S1](#app1-jcm-07-00246){ref-type="app"}. We corrected these imbalances in baseline patient characteristics by stabilized IPTW estimation using propensity scores.

Comorbidities on first admission for chemotherapy with CPT-11 are presented in [Table 2](#jcm-07-00246-t002){ref-type="table"}. There were more patients with chronic obstructive pulmonary disease in the TJ-14 group; we also corrected this imbalance by stabilized IPTW estimation.

3.2. Tolerability of CPT-11 {#sec3dot2-jcm-07-00246}
---------------------------

To examine the tolerability of CPT-11, we analyzed the dosage of CPT-11 administered in TJ-14 and control groups. In all patients, mean frequency and amount of CPT-11 administered on first admission were significantly greater in the TJ-14 than the control group. Mean frequencies were 1.55 (SD 1.31) in the control group and 2.22 (SD 2.06) in the TJ-14 group (*p* \< 0.001). Mean total doses (milligrams) were 222 (SD 143) in the control group and 262 (SD 222) in the TJ-14 group (*p* \< 0.001). The generalized linear model in patients after stabilized IPTW estimation showed that the incidence rate ratio of CPT-11 administration was 1.34 (95% confidence interval (CI), 1.31--1.38; *p* \< 0.001) for frequency and 1.16 (95% CI, 1.14--1.19; *p* \< 0.001) for total dose. To remove hidden biases caused by unmeasured confounders, we confirmed the results of tolerability of CPT-11 by IV analysis. Our IV analysis had an F-statistic of 4352 with *p* \< 0.001. The incidence rate ratio of CPT-11 administration was 1.11 (95% CI, 1.05--1.17; *p* \< 0.001) for frequency, and 1.12 (95% CI, 1.11--1.12; *p* \< 0.001) for total dose. These results are shown in [Table 3](#jcm-07-00246-t003){ref-type="table"}.

3.3. Mortality during First Admission for Administration of CPT-11 {#sec3dot3-jcm-07-00246}
------------------------------------------------------------------

Among all patients, 3972 (4.8%) in the control and 336 (4.6%) in the TJ-14 group died during the first observed hospitalization for chemotherapy with CPT-11. Crude mortality did not differ significantly between the two groups (*p* = 0.26). However, after stabilized IPTW estimation, mortality was significantly lower in the TJ-14 (4.0%) than the control group (4.8%) (*p* = 0.001). In stabilized IPTW analysis, the odds ratio of in-hospital mortality in the TJ-14 group was 0.81 (95% CI, 0.71--0.93; *p* = 0.002) compared with the control group. In IV analysis, the odds ratio of in-hospital mortality in the TJ-14 group was 0.42 (95% CI, 0.22--0.80; *p* = 0.009) compared with the control group. [Table 4](#jcm-07-00246-t004){ref-type="table"} shows in-hospital mortality on first observed hospitalization for chemotherapy with CPT-11 with or without TJ-14.

4. Discussion {#sec4-jcm-07-00246}
=============

The current study showed that administration of TJ-14 is significantly associated with decreased mortality and increased dosage of first CPT-11 during hospitalization. To the best of our knowledge, this is the first published evidence that TJ-14 improves the tolerability of CPT-11 in a nationwide clinical setting.

In earlier studies, baicalein was found to inhibit β-glucuronidase activity with SN-38-glucuronide as substrate in vitro \[[@B10-jcm-07-00246]\]. TJ-14 and baicalein inhibited deconjugation of SN-38-glucuronide and ameliorated diarrhea symptoms induced by CPT-11 in an animal model \[[@B4-jcm-07-00246]\]. The results of these earlier studies suggest that TJ-14 and baicalein are effective in improving tolerability of CPT-11. TJ-14 is recommended for patients receiving chemotherapy with CPT-11 in a Japanese stewardship guide. However, in clinical settings, TJ-14 has been reported to be effective against CPT-11 toxicity in only 41 patients with non-small cell lung cancer \[[@B5-jcm-07-00246]\]. Consequently, thus far, TJ-14 has only been used in Japan in patients receiving chemotherapy with CPT-11. The current study is the first to provide evidence that TJ-14 significantly improves the tolerability of CPT-11 regardless of cancer type on the basis of retrospectively examining data for a large nationwide clinical cohort.

We conducted a quasi-experimental study using two different pseudorandomization techniques (IPTW analysis using propensity scores and IV analysis) to examine the efficacy of TJ-14 against CPT-11 toxicity. Performing IV analysis allowed us to control for hidden biases caused by unmeasured confounders that are not removed by IPTW or a generalized linear model. IV analysis also showed that TJ-14 had a beneficial effect on mortality with a lower point estimate of risk compared with propensity score analysis. IV analysis only evaluates the effectiveness of the treatment in a patient group changing treatment according to the instrumental variable (i.e., local average treatment effect) \[[@B11-jcm-07-00246]\]. This effect may thus be strong because it was small that the number of patients who might have received TJ-14 if they had been in a hospital that tended to use TJ-14 with CPT-11, according to the IV. Taken together, we consider that the demonstrated efficacy of TJ-14 against CPT-11 toxicity in the current study provides robust evidence for using it as supportive therapy in patients receiving CPT-11.

In this study, we were not able to take into account the severity of adverse effects of CPT-11; e.g., diarrhea and febrile neutropenia. We, therefore, did not evaluate the incidence of diarrhea or febrile neutropenia as endpoints of this study. Instead, we evaluated prescription of antidiarrheal agents (loperamide and lactobacillus preparations) and the use of granulocyte colony-stimulating factor as variables in stabilized IPTW and IV analysis. We believe that our stabilized IPTW and IV analysis did thereby adjust for these adverse effects, thus accurately evaluating the efficacy of TJ-14 against CPT-11 toxicity.

This study has some limitations. First, we could not determine therapies administered prior to chemotherapy with CPT-11 or causes of in-hospital deaths. However, we believe that the effects of prior therapies or causes of death would have been adjusted for by the IV analysis. Our study thus may have accurately evaluated the efficacy of TJ-14. Second, we were also unable to take into consideration genetic polymorphisms on UDP-glucuronosyl transferase 1A1 (UGT1A1), which predominantly inactivates SN-38 to form a glucuronide metabolite. About 10% of patients with reduced UGT1A1 activity are at increased risk for diarrhea and neutropenia \[[@B12-jcm-07-00246],[@B13-jcm-07-00246]\]. However, it is unlikely that UGT1A1 activity biased the selection of treatment with TJ-14 in patients receiving CPT-11. Third, we evaluated only the initial hospitalization episode for each patient treated with CPT-11 with the intent of capturing the first course of chemotherapy with CPT-11 because the dosage or intervals between administrations of CPT-11 may have been reduced or prolonged because of adverse drug reactions in subsequent courses. However, we may not have succeeded in capturing the first course of chemotherapy with CPT-11 in some cases. For example, patients who had switched hospitals for subsequent courses of a CPT-11 regimen, started a CPT-11 regimen as an outpatient but subsequently been hospitalized (e.g., because of an adverse drug reaction), or had been in hospitals that started to provide DPC data after initiation of CPT-11 may have erroneously been treated as though the studied hospitalization for administration of CPT-11 was the first. However, it is likely that most assessed episodes were for the first course of a CPT-11 regimen. Moreover, the reason for not evaluating outpatients was that environmental factors that may affect outcomes can be minimized in hospitalized patients.

5. Conclusions {#sec5-jcm-07-00246}
==============

The present study of data extracted from a nationwide database and examined using two pseudorandomization techniques, stabilized IPTW and IV, provides evidence that TJ-14 improves the tolerability of CPT-11 in hospitalized patients. We therefore recommend TJ-14 as a useful supportive therapy for patients receiving CPT-11.

The following are available online at <http://www.mdpi.com/2077-0383/7/9/246/s1>, Table S1: Detailed information of cancer types of all patients.

###### 

Click here for additional data file.
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jcm-07-00246-t001_Table 1

###### 

Baseline characteristics of patients on first admission for CPT-11 chemotherapy with or without TJ-14, before and after stabilized inverse probability treatment weighting using propensity scores.

  ---------------------------------------------------------------------------------------------------------------------------------------------
  Characteristic (Categorical)   All Patients   Patients after IPTW Estimation                                                         
  ------------------------------ -------------- -------------------------------- ------ ------ -------- -------- ------ ------- ------ --------
  Sex (male)                     49,417         59.4                             4347   60.1   0.012    48,732   59.4   4195    59.2   0.006

  Cancer type ^a^                                                                                                                      

  Colon cancer                   36,595         44.0                             1937   26.8   −0.37    34,958   42.6   3004    42.4   −0.006

  Lung cancer                    14,271         17.2                             2438   33.7   0.39     15,165   18.5   1351    19.1   0.013

  Gastric cancer                 11,078         13.3                             571    7.9    −0.18    10,560   12.9   914     12.9   0.000

  Ovarian cancer                 4438           5.3                              589    8.1    0.11     4586     5.6    408     5.8    0.006

  Pancreatic cancer              4421           5.3                              317    4.4    −0.044   4310     5.3    359     5.1    −0.009

  Cervical cancer                4039           4.9                              452    6.2    0.058    4074     5.0    356     5.0    0.002

  Non-Hodgkin lymphoma           1042           1.3                              170    2.4    0.083    1093     1.3    100     1.4    0.006

  Breast cancer                  311            0.4                              28     0.4    0.005    300      0.4    23      0.3    −0.007

  Skin cancer                    88             0.1                              26     0.4    0.051    105      0.1    9       0.1    −0.000

  Other cancer                   7098           8.5                              736    10.2   0.057    7057     8.6    581     8.2    −0.014

  Activities of daily life\                                                                                                            
  (Barthel index)                                                                                                                      

  Independent (100)              72,572         87.2                             6293   86.9   −0.007   71,717   87.4   6184    87.2   −0.008

  Dependent (≤95)                7638           9.2                              675    9.3    0.003    7463     9.1    676     9.5    0.015

  Missing                        2988           3.6                              271    3.7    0.009    2839     3.5    232     3.3    −0.010

  Characteristic (numerical)     Mean           S.D.                             Mean   S.D.   s.d.     Mean     Mean   s.d.           

  Age (years)                    64.5           10.9                             64.0   11.3   −0.004   64.4     64.6   0.015          

  Body mass index (kg/m2)        21.9           3.7                              22.1   3.8    0.063    21.9     21.9   0.001          
  ---------------------------------------------------------------------------------------------------------------------------------------------

^a^ overlapping of cancer types, detailed information in [Supplementary Materials](#app1-jcm-07-00246){ref-type="app"}; IPTW, inverse probability treatment weighting; s.d., standardized difference; S.D., standard deviation.

jcm-07-00246-t002_Table 2

###### 

Comorbidities on first admission for CPT-11 chemotherapy with or without TJ-14, before and after stabilized inverse probability treatment weighting using propensity scores.

                                          All Patients   Patients after IPTW Estimation                                                 
  --------------------------------------- -------------- -------------------------------- ----- ----- -------- ------ ----- ----- ----- --------
  Chronic obstructive pulmonary disease   2611           3.1                              387   5.4   0.11     2725   3.3   236   3.3   0.001
  Interstitial pneumonia                  477            0.6                              66    0.9   0.041    492    0.6   43    0.6   0.000
  Congestive heart failure                1996           2.4                              188   2.6   0.013    1347   2.4   117   2.4   −0.003
  Ischemic heart disease                  2571           3.1                              278   3.8   0.040    2587   3.2   238   3.4   0.011
  Tachycardia                             1937           2.3                              209   2.9   0.036    1947   2.4   172   2.4   0.003
  Chronic liver disease                   1554           1.9                              134   1.9   −0.001   1525   1.9   142   2.0   0.010
  Chronic renal failure                   1224           1.5                              123   1.7   0.020    1225   1.5   98    1.4   −0.009
  Autoimmune disease                      585            0.7                              61    0.8   0.017    586    0.7   52    0.7   0.002

IPTW, inverse probability treatment weighting; s.d., standardized difference.

jcm-07-00246-t003_Table 3

###### 

Incidence rate ratios of CPT-11 administration with TJ-14 compared with without TJ-14 by generalized linear models and instrumental variable analyses.

  CPT-11 Administration   Generalized Linear Model   Instrumental Variable Analysis                                 
  ----------------------- -------------------------- -------------------------------- --------- ------ ------------ ---------
  frequency               1.34                       1.31--1.38                       \<0.001   1.11   1.05--1.17   \<0.001
  amount                  1.16                       1.14--1.19                       \<0.001   1.12   1.11--1.12   \<0.001

IRR, incidence rate ratio; CI, confidence interval.

jcm-07-00246-t004_Table 4

###### 

In-hospital death on first admission for CPT-11 administration with or without TJ-14.

                                                             All Patients               Patients after IPTW Estimation                                                               
  ---------------------------------------------------------- -------------------------- -------------------------------- ------- ------------ ------------ ------- ----- ----- ----- -------
  In-hospital death                                          3972                       4.8                              336     4.6          0.26         3936    4.8   280   4.0   0.001
                                                             Generalized linear model   Instrumental variable analysis                                                               
                                                             Odds ratio                 95% CI                           *p*     Odds ratio   95% CI       *p*                       
  In-hospital mortality of TJ-14 compared with the control   0.81                       0.71--0.93                       0.002   0.42         0.22--0.80   0.009                     

IPTW, inverse probability treatment weighting; CI, confidence interval.
